Tirzepatide Approved for Expanded Use in Europe, Targeting Obesity and Heart Failure
European regulators have broadened the approved uses of tirzepatide, a medication initially developed for type 2 diabetes, to now include treatment for obesity and certain types of heart failure. This expansion signifies a growing recognition of the drug’s potential beyond glucose control and highlights a shift towards comprehensive metabolic health management.
Tirzepatide, marketed under the brand name Mounjaro, works by increasing insulin levels in the body, which lowers blood sugar. It also reduces the amount of sugar released into the bloodstream and slows down digestion, according to the Cleveland Clinic. The medication is administered as an injection once weekly.
The European Medicines Agency (EMA) has updated the drug’s authorization to encompass adults with obesity, offering a fresh pharmacological option for managing a condition with significant health implications. The EMA has approved its use in treating a specific form of heart failure. This decision follows positive clinical trial data demonstrating the drug’s efficacy in these areas.
Tirzepatide is a GIP and GLP-1 receptor agonist, mimicking the action of natural hormones in the body, as explained by Drugs.com. Available in various strengths – 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg per 0.5 mL – it’s delivered via single-dose pens and vials.
Common side effects associated with tirzepatide include nausea, diarrhea, decreased appetite, and vomiting. Patients should discuss any bothersome side effects with their healthcare provider. As with any medication, regular monitoring by a healthcare professional is crucial while taking tirzepatide, the Cleveland Clinic notes.
Originally indicated for type 2 diabetes, Mounjaro helps lower blood sugar levels by increasing insulin production when glucose levels rise, preventing the liver from releasing stored sugar, and slowing absorption of food and drink, according to WebMD. The drug is available as a solution for injection in prefilled pens and vials.
Proper storage of Mounjaro is essential. It should be kept in its original packaging in the refrigerator, between 36°F and 46°F (2°C and 8°C). Brief exposure to temperatures up to 86°F (30°C) for no more than 21 days is permissible.
